Podcasts about psvt

Paroxysmal supraventricular tachycardia (PSVT) is a sudden-onset tachyarrhythmia that can cause palpitations, chest discomfort, and dyspnea. JAMA Associate Editor David Simel, MD, MHS, discusses the diagnosis and treatment of patients with PSVT with author Paul Zei, MD, of Harvard University. Related Content: Diagnosis and Management of Paroxysmal Supraventricular Tachycardia Modified Valsalva Maneuver (video) Carotid Sinus Massage (video)

Matt Bachman is in charge of the Commercial Operations for Milestone Pharmaceutical company, a biotech company launching a novel treatment for patients with PSVT. Jasmeet and Matt discuss the intricacies of building a commercial function for an emerging pharma company, with Matt highlighting distinctions between working in a large pharmaceutical company versus a smaller one. They also delve into crucial factors influencing decision-making for the future, with a particular emphasis on the formidable challenge of navigating data considerations. Matt introduces a compelling and reflective concept, emphasizing that decisions must be "Fit for Purpose.” That is sound learning, no matter the size of your organization.    IN THIS EPISODE: [2:32] Matt discusses the key differences between working for large pharmaceutical companies and his current position [3:41] Matt explains his vision for setting up the commercial function [5:50] Matt discusses how he decides what priorities are needed for Milestone to benefit the company  [8:05] Matt shares what components he wants to implement to build a foundation for data-driven commercialization, and he is developing a data governance system [13:16] Matt speaks to the technologies and capabilities that they are planning for the future and how he is putting his team together  [17:27]  Matt shares what he has learned in the process of setting up the commercial function KEY TAKEAWAYS In a smaller company, when you don't have the resources of a large entity, you have to determine the must-haves and what things would be nice to have. You need to be able to make adjustments quickly for growing or scaling back.  Connecting with stakeholders, department heads, and other management figures in a smaller organization is more straightforward. The absence of a sprawling corporate structure, as seen in larger companies, facilitates smoother and faster communication.   A company can make a big mistake by spending resources on collecting data, and then they find out it needs to be more accurate data. The perfect time to make data governance decisions is when you are starting out before you start collecting massive amounts of data you won't ever use.    BIOGRAPHY:  Matt Bachman brings over 20 years of experience in the insights and analytics arena at both large pharma and small biotech companies. During that time, he has worked closely with brand teams to commercialize numerous drugs in multiple therapeutic areas. These include drugs for type 2 diabetes and cardiovascular drugs that were first in class and novel therapies, as well as the ones that had little clinical differentiation, which presents its own set of challenges. From a customer standpoint, he has worked on commercializing drugs that targeted specialists and also the ones that targeted broad-based PCPs. He currently leads the commercial operations for Milestone Pharmaceuticals, a small biotech company launching a novel treatment for patients with PSVT. Before Milestone, Matt worked for large companies like GSK and BMS. YOUR HOST: JASMEET SAWHNEY    Jasmeet Sawhney is a life sciences industry executive, marketing leader, and serial entrepreneur with deep roots in technology and data analytics. He is currently the global head of marketing at Axtria. Jasmeet has over 20 years of experience in the life sciences domain and has helped build and scale three successful companies. He has received several company and individual awards, including Inc 500, Deloitte Fast 500, Crain's NY Fast 50, NJBiz Fast 50, Business of the Year, SmartCEO Future 50, Top CMO, Forty Under 40, and many more. Jasmeet Sawhney - LinkedIn Axtria on LinkedIn Matthew Bachman - LinkedIn  

In this podcast, Dr Lip and Dr Stambler discuss the RAPID trial (NCT03464019), which was a phase 3 study that evaluated the safety and efficacy of etripamil in terminating PSVT episodes using a repeat-dosing regimen. RAPID was a multicenter, randomized trial that enrolled adults with electrocardiograph (ECG)-documented PSVT episodes lasting ≥ 20 min. This podcast is published open access in Cardiology and Therapy and is fully citeable. You can access the original published podcast article through the Cardiology and Therapy website and by using this link: [https://link.springer.com/article/10.1007/s40119-023-00335-4]. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.  

Take 1 minute to tell us what you think about this episode: pcna.net/PSVTevalGuest Mary Janette Sendin, MSN, APRN-CNS, CCNS, PCCN describes traditional pharmacologic and non-pharmacologic treatment options for PSVT such as vasovagal technique. Janette also discusses current research into treatment options.ESC Guideline: Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720.AHA Guideline: Page RL, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133(14):e506-e574. Etripamil study: Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Take 1 minute to tell us what you think about this episode: pcna.net/PSVTevalKathryn Wood, PhD, RN, FAHA, FAAN, discusses paroxysmal supraventricular tachycardia (PSVT) and other similar episodic rapid heart rate conditions. Dr. Wood describes pathophysiology, prevalence, symptoms, and disparities related to diagnosis and treatments, and also shares helpful resources for both providers and patients.Kathy Wood's 2015 paper with PSVT images and details: Wood K. Mechanisms and clinical manifestations of supraventricular tachycardias. Prog Cardiovasc Nurs. 1995;10(2):3-14.Symptom research: Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol. 1997;79(2):145-149.Symptom research: McCabe PJ, Chamberlain AM, Rhudy L, DeVon HA. Symptom Representation and Treatment-Seeking Prior to Diagnosis of Atrial Fibrillation. West J Nurs Res. 2016;38(2):200-215.Symptom research: McCabe PJ, Rhudy LM, Chamberlain AM, DeVon HA. Fatigue, dyspnea, and intermittent symptoms are associated with treatment-seeking delay for symptoms of atrial fibrillation before diagnosis. Eur J Cardiovasc Nurs. 2016;15(6):459-468.Symptom research: McCabe PJ, Rhudy LM, DeVon HA. Patients' experiences from symptom onset to initial treatment for atrial fibrillation. J Clin Nurs. 2015;24(5-6):786-796.Symptom research: Streur M, Ratcliffe SJ, Callans D, Shoemaker MB, Riegel B. Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis. Eur J Cardiovasc Nurs. 2018;17(8):707-716.Disparities: Gleason KT, Nazarian S, Dennison Himmelfarb CR. Atrial Fibrillation Symptoms and Sex, Race, and Psychological Distress: A Literature Review. J Cardiovasc Nurs. 2018;33(2):137-143.Patient preferences in AFib education: Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management (EHRA, HRS, APHRS, SOLEACE consensus document). Europace. 2015;17(12):1747-1769. DOI: 10.1093/europace/euv233ESC Guidelines: Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.AHA My AFib Experience: https://supportnetwork.heart.org/s/myafibmainStopAFib.orgSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Take 1 minute to tell us what you think about this episode: pcna.net/PSVTevalGuests Mary Janette Sendin, MSN, APRN-CNS, CCNS, PCCN, and Daniel Weinstein discuss the patient journey for those with PSVT, and the challenges that can delay diagnosis for some individuals. The importance of patient-centered care in the healthcare setting and beyond is also part of the conversation.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This activity was supported by an educational grant from Milestone Pharmaceuticals. Please go to academiccme.com/PSVTpodcast/ and complete the evaluation to receive your CE/CME Credit.

This activity was supported by an educational grant from Milestone Pharmaceuticals. Please go to academiccme.com/PSVTpodcast/ and complete the evaluation to receive your CE/CME Credit.

Digoxin also goes by the brand names Digox, Digitalis, and Lanoxicaps. Digoxin comes as tablets, a solution, and an injection. In both Adults and Pediatrics, when calculating doses it is important to use the patient's lean body weight (LBW) with dose adjustments based on levels. It is important to also remember that concentrations of >2 ng/mL lead to digoxin toxicity and can also be identified with signs and symptoms such as anorexia, nausea, vomiting, and visual changes. The most common indications are for treating Heart Failure with reduced Ejection Fraction (HFrEF) and Atrial Fibrillation (AFib). Digoxin is poorly protein bound with a long duration of action between 3-4 days. THe most common side effects are dizziness, headache, bradycardia, weakness, and confusion. FREE Drug Card Sheet is available for this episode at DrugCardsDaily.com along with ALL past FREE drug card sheets! Please SUBSCRIBE, FOLLOW, and RATE on Spotify, Apple Podcasts, or wherever your favorite place to listen to podcasts are. I'd really appreciate hearing from you! Leave a voice message at anchor.fm/drugcardsdaily or find me on most all socials @drugcardsdaily or send an email to contact.drugcardsdaily@gmail.com to leave feedback, request a drug, or say hello! --- Send in a voice message: https://anchor.fm/drugcardsdaily/message

Sometimes in medicine, we do things just because they’ve always been done that way, which is terrible reasoning. Valsalva maneuver followed by the two-syringe technique for adenosine administration has been standard practice in PSVT management for decades. Recent data suggests that both of these approaches may have better alternatives. Join Dr. Patrick and Brad Ward as they provide updates on both non-pharmacologic and pharmacologic management of PSVT. REFERENCES 1. McDowell M et al. Single-Syringe Administration of Diluted Adenosine. Acad Emerg Med 2020, Jan;1:62-63. 2. Choi SC et al. A Convenient Method of Adenosine Administration for Paroxysmal Supraventricular Tachycardia. J Korean Soc Emerg Med 2003, Aug;14(3):224-227. 3. Weberding NT, Saladino RA, Minnigh MB, et al. Adenosine administration with a stopcock technique delivers lower-than-intended drug doses. Ann Emerg Med 2018;71:220–4. 4. https://www.youtube.com/watch?v=8DIRiOA_OsA

Sheryl Chan is the writer behind A Chronic Voice, a blog that aims to articulate lifelong illnesses through various perspectives. She herself lives with multiple diagnoses, which include autoimmune disorder antiphospholipid syndrome, Sjögren's syndrome, epilepsy, lupus (SLE) and more. Beginning with a mini stroke at the age of 14, Sheryl’s experience was followed by multiple blood clots in the lungs and legs, a gore-tex band for a heart valve (she then developed PSVT — paroxysmal supra ventricular tachycardia — after this mitral valve repair in 2011), seizures, scars from various surgeries, and ongoing chronic pain associated with lupus. She’s been in out and out of hospital rooms for so long, she knows what it’s like to face mortality and to battle the mental health after-effects of such critical situations. One thing Sheryl truly works to destigmatize is mental health — from depression to anxiety and everything in between, she hopes that by sharing her experiences, she can share that it’s OK…to not be OK. As she says, “Let us simply get through it together one day at a time…and if need be, one second at a time. I can, I can, I can. That’s three seconds down.” Tune in as Sheryl shares: that she had a mild stroke at 14, at which point blood clotting disorder antiphospholipid syndrome (APS) was diagnosed that she has to take blood thinners daily in order to prevent clotting that APS is usually diagnosed in late-stage pregnancy, as it can cause miscarriage — so Sheryl was unusual in that her case was diagnosed sooner that at 17, she had her first brush with death when she suffered a massive blood clot in her lung — and a doctor didn’t take her seriously at first that because the episode with APS at 17 was so severe, it likely triggered the genes for lupus, Sjögren’s, and more that her second brush with death came at 25, when one of her heart valves prolapsed that she raised funds ($100K USD) to have her prolapsed valve repaired at the Cleveland Clinic with minimally-invasive techniques that because of her experiences, she is no longer afraid of death how she is constantly balancing her mental health and chronic pain how she’s become her own advocate, and become skilled at firing doctors who aren’t working with her that her medications cost $1-2K/month, despite a chronic illness payment scheme that pain is often not the worst part of chronic illness: isolation and fatigue can be just as difficult to deal with that mental health issues come along with all chronic illnesses at some point — and need to be taken care of from diagnosis. Sheryl recommends adding a therapist to your medical team ASAP why it’s important for all your doctors to work with you, and be open to communicating as a team why it’s important to trust yourself and your own knowledge of our body why it’s important to ask for help and seek community

You may not have heard of PSVT but chances are you’ve experienced the symptoms of this condition. These can be frightening and anxiety producing if you aren’t familiar with what to do. Our guest is Donnette Smith is the president of Mended hearts. She joins us to share all about paroxysmal supraventricular tachycardia and the steps you can take if you think you may be suffering from the condition.  So, if you care about aging well and spending many more years with your grandchildren, you won’t want to miss this one!

Välkommen till novemberavsnittet av AKUTBOKEN podcast. Här är ämnena och artiklarna i detta avsnitt: Modifierad Valsalva för behandling av SVT Çorbacıoğlu et al. (2017) Comparing the success rates of standard and modified Valsalva maneuvers to terminate PSVT.  Am J Emerg Med. (11):1662-1665. PMID: 28552271 Film som visar modifierad Valsalva  Tranexamsyra (Cyklokapron) vid livshotande blödning Gayet-Ageron et […]

  This week brings around new research from an international study that claims an average sodium intake does not harm your health; NSERC grants 1.65 million for a new biomedical technology program; Prometic Life Sciences elucidates the mechanism of action of their proprietary drug; and Milestone Pharmaceuticals randomises their first patient in their phase 3 clinical trial.   Keep on listening to hear all the juicy details!   +++++  No need to fret when you ask someone to pass you the salt at the dinner table anymore. New research by scientists of the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences as well as researchers from 21 countries suggests sodium intake does not increase health risks except for those who eat more than five grams a day – an equivalent of 2.5 teaspoons.  This large-scale international study expresses for most individuals that this is good news. Any health risk of sodium consumption is virtually eliminated if people improve their diet quality by adding fruits, vegetables, dairy foods, potatoes, and other potassium rich foods.  The study followed 94,000 people, aged 35 to 70, for an average of eight years in communities from 18 countries around the world and found there an associated risk of cardiovascular disease and strokes only where the average intake is greater than five grams of sodium a day.  China is the only country in their study where 80 per cent of communities have a sodium intake of more than five grams a day. In the other countries, most communities had an average sodium consumption of 3 to 5 grams a day.  The World Health Organization recommends consumption of less than two grams of sodium — that’s one teaspoon of salt — a day as a preventative measure against cardiovascular disease, but there is little evidence in terms of improved health outcomes that individuals ever achieve at such a low level.  The American Heart Association recommends even less — 1.5 grams of sodium a day for individuals at risk of heart disease.  Andrew Mente, first author of the study and a PHRI researcher says, “Only in the communities with the most sodium intake — those over five grams a day of sodium – which is mainly in China, did we find a direct link between sodium intake and major cardiovascular events like heart attack and stroke. In communities that consumed less than five grams of sodium a day, the opposite was the case. Sodium consumption was inversely associated with myocardial infarction or heart attacks and total mortality, and no increase in stroke.”  Researchers found that all major cardiovascular problems – including death – decreased in communities and countries where there is an increased consumption of potassium which is found in foods such as fruits, vegetables, dairy foods, potatoes and nuts, and beans.  Martin O’Donnell, co-author of the report, an associate clinical professor of medicine at McMaster says that most previous studies relating sodium intake to heart disease and stroke were based on individual-level information, and that public health strategies should be based on best evidence.   Their findings demonstrate that community-level interventions to reduce sodium intake should target communities with high sodium consumption and should be embedded within approaches to improve overall dietary quality. There is no convincing evidence that people with moderate or average sodium intake need to reduce their sodium intake for prevention of heart disease and stroke.  This study lends a hand to simmer down those creeping thoughts of sodium consumption and health issues. Of course, it is still best to use in moderation; but next time someone asks you to pass the salt, you can now more comfortably allow your worry to subside.  +++++  Medical innovations improve and save lives. It for this reason that Canada invests so heavily into the health and life sciences. But when it comes to health technology, innovative designs like prosthetic limbs or pacemakers must be designed by a special type of engineer – one who solve engineering problems and can identify medical technology needs.    Catherine Burns, professor of systems design engineering and executive director of the Centre for Bioengineering and Biotechnology, has been awarded a Collaborative Research and Training Experience Program (CREATE) grant to establish a biomedical engineering graduate program that will help produce this type of engineer. The $1.65 million grant awarded by the Natural Sciences and Engineering Research Council of Canada (NSERC) will help fund a new program in global biomedical technology research and innovation at Waterloo starting in the fall of 2018, the only one of its kind in Canada.  Burns says that most students come out of biomedical engineering graduate programs as great researchers, but not necessarily with a good understanding of how the industry works. That this program will produce students who know both the research side and the business side of the industry.  To understand the needs of medical technology users, students will get out into the field to work alongside clinicians and patients to better understand real-life scenarios before developing solutions.  Grand River Hospital is one of the partners to the program, as well as Starfish Medical and Synaptive Medical – both of which are very successful Canadian medical device companies.  The curriculum at Waterloo will include clinic and industry internships, commercialization courses, international exchanges, and professional skills workshops. Students will graduate knowing how to work with patients and clinicians with understanding of medical device regulation. They will also have the skills and industry contacts in place to help secure jobs in the biomedical industry or commercialize their own inventions.  Charmaine Dean, the vice president of university research  says that the technical expertise, professional skills, and interdisciplinary experience students gain in this program will produce biomedical engineers capable of transforming the Canadian health technology landscape and is another step in growing Waterloo’s role in the biotechnology and research ecosystem.  There is a proposed initiative for the program at Toronto Western Hospital, where a Critical Care physician manages a large amount of data on brain injuries. The goal would be to integrate the data with data from laboratory and patient records, which will provide new insights into the complex physiological relationships in brain injury patients. Students in the program will work with the physician to acquire an understanding of brain injuries, and then develop a data integration solution.  Each student will be part of a team that includes a research supervisor, a clinician, and the manager of a biomedical engineering company. Before commencing their research, students will need to prove that they’ve spent time with clinicians and patients in settings relevant to their area of research. This will help ensure that the solutions they develop are viable and easier to commercialise.  Overall, this one-of-a-kind program will continue to make Canada an economic powerhouse and punch above its weight in health and life sciences.  +++++  Prometic Life Sciences Inc. announces the publication of a paper that further elucidates the mechanism of action of its lead drug candidate, PBI-4050, on liver fibrosis in the Journal of Pharmacology and Experimental Therapeutics.   The drug’s clinical activity has already been shown to significantly reduce liver and cardiac fibrosis in patients in the ongoing Phase 2 clinical trial in patients with Alström syndrome.  Dr. Lyne Gagnon, senior author of the paper and Prometic’s vice president of R&D says that studying the mechanism of action of PBI-4050 in liver diseases, including non-alcoholic steatohepatitis (NASH), has clearly demonstrated that PBI-4050 acts through a major signaling AMPK pathway, thus linking metabolism to fibrosis. The data shows the potential therapeutic effects of PBI-4050 in liver fibrosis and non-alcoholic steatohepatitis.  There are several stages of liver fibrosis, and if left untreated or without changing significant lifestyle choices, may lead to liver cirrhosis.  Pierre Laurin, chief executive officer of Prometic adds that they have seen the benefits of PBI-4050 in reducing liver fibrosis in Alström syndrome patients. With this further validation that the signaling pathway targeted by PBI-4050 is indeed at the core of the genesis of fibrosis in the liver, they are very confident about its potential to address fibrosis-related conditions such as Alström syndrome, and non-alcoholic steatohepatitis. We look forward to initiating our Phase 3 pivotal clinical trial for PBI-4050 in IPF and expanding the program in Alström syndrome.”  +++++  Milestone Pharmaceuticals, a clinical-stage cardiovascular company, randomises their first patient in its Phase 3 clinical study of etripamil. Etripamil is a new investigational, rapid-onset, short-acting calcium channel blocker administered intranasally by the patient designed to terminate paroxysmal supraventricular tachycardia (PSVT) episodes wherever they occur.  paroxysmal supraventricular tachycardia is a recurring and sporadic heart arrhythmia caused by abnormalities in the cardiac conduction system. The current standard of care to terminate these episodes is intravenous medication delivered in the emergency department.  The Phase 3, multicenter, randomized, double-blind, placebo-controlled, event-driven study is planned to be conducted in more than 50 cardiology centers in the United States and Canada and will enroll up to 500 patients. Following an in-office test dose of etripamil, patients will take home either 70 mg of etripamil or placebo for when a paroxysmal supraventricular tachycardia episode occurs. Upon onset of an episode, patients will apply a wireless cardiac monitor to their chest to record their heart rhythm, perform a vagal maneuver, and if symptoms persist, administer study drug.  Bruce Stambler, MD, FHRS, Piedmont Heart Institute says that the design of the NODE-301 study of etripamil will allow them to obtain more clinical evidence of the benefits of this potential treatment for paroxysmal supraventricular tachycardia in an outpatient, real-world setting. paroxysmal supraventricular tachycardia is an unpredictable disorder and the potential for a fast-acting therapy to resolve the symptoms of paroxysmal supraventricular tachycardia wherever the episodes occur could significantly reduce the burden this condition puts on patients and the health care system.  The primary endpoint of the study is time to conversion of paroxysmal supraventricular tachycardia to sinus rhythm after the administration of study drug as confirmed by a central independent adjudication committee. Secondary study endpoints include relief of symptoms commonly associated with an episode of paroxysmal supraventricular tachycardia such as heart palpitations, chest pain, anxiety, shortness of breath, dizziness, and fainting.  Francis Plat, MD, Milestone’s Chief Medical Officer  says that the initiation of the NODE-301 study is an example of our ongoing commitment to improve the lives of patients with paroxysmal supraventricular tachycardia. Etripamil, if approved by regulatory authorities, could empower patients to take control of this anxiety-producing arrhythmia without being reliant on chronic medications or trips to an acute-care facility for treatment.  The study will enroll patients at least 18 years of age with a documented history of paroxysmal supraventricular tachycardia. Patients receiving study treatment in NODE-301 will be eligible to participate in an open-label extension study (NODE-302) where etripamil will be provided for subsequent paroxysmal supraventricular tachycardia episodes.  There are well over a million people in the US living with paroxysmal supraventricular tachycardia, resulting in hundreds of thousands of emergency department and doctor’s office visits each year. There are countless other patients who exist and don’t seek care, suffering through their episodes in silence as the current approved treatment options are unpleasant, inconvenient, and/or costly.  Providing a way to self-manage paroxysmal supraventricular tachycardia episodes could offer immediate relief for those living with this arrhythmia.  +++++  Well that’s it for this week! If you have a story idea, please feel free to reach out to me at press@promotivemedia.ca and be sure to check out the stories in full at our website biotechnologyfocus.ca. Until next time, from my desk to yours – this is Michelle Currie.

Microsoft teases a streaming service, Skyrim gets a PSVT bundle, PlayStation Trophies get you rewards, Watch Dogs is free, and Jeff plays Horizon: Zero Dawn’s expansion, The Frozen Wilds.

> Atrial fibrillation Fibrillation Muscular twitching involving individual muscle fibers acting WITHOUT coordination The most common chronic arrhythmia Onset is PSVT before becoming chronic First event will spontaneously convert 60% of the time within the first 24 hrs Risk Factors […] The post S2 E022 Afib & Aflutter appeared first on Physician Assistant Exam Review.

Dr. Pescatore and Ms. Roberts discuss hot topics in the March issue, including topical anesthetics for corneal abrasions, a vagal maneuver for PSVT, and much more. Plus an interview with Dr. Andrew Nyce, the residency director at Cooper Medical School in Camden, NJ, about the symbiosis of urgent care and the ED.

On this podcast we review some background on AVNRT and focus on Emergency Department management. https://media.blubrry.com/coreem/content.blubrry.com/coreem/Episode_20_0_Final.m4a Download 2 Comments Tags: AVNRT, PSVT, REVERT Trial, Tachydysrhythmias Show Notes AVNRT with Aberrancy vs. VT REBEL EM: SVT with Aberrancy Versus VT Amal Mattu's ECG Case of the Week: August 26th, 2013 Valsalva Maneuver ALiEM: Tricks of the Trade: Valsalva Maneuver By Using a 10cc Syringe St. Emlyn's: JC The REVERT Trial Adenosine in AVNRT Larry Mellick: Treating SVT with Adensoine ALiEM: Trick of the Trade: Combining Adenosine with the Flush Verapamil in AVNRT RAGE Podcast:

On this podcast we review some background on AVNRT and focus on Emergency Department management. https://media.blubrry.com/coreem/content.blubrry.com/coreem/Episode_20_0_Final.m4a Download 2 Comments Tags: AVNRT, PSVT, REVERT Trial, Tachydysrhythmias Show Notes AVNRT with Aberrancy vs. VT REBEL EM: SVT with Aberrancy Versus VT Amal Mattu’s ECG Case of the Week: August 26th, 2013 Valsalva Maneuver ALiEM: Tricks of the Trade: Valsalva Maneuver By Using a 10cc Syringe St. Emlyn’s: JC The REVERT Trial Adenosine in AVNRT Larry Mellick: Treating SVT with Adensoine ALiEM: Trick of the Trade: Combining Adenosine with the Flush Verapamil in AVNRT RAGE Podcast:

On this podcast we review some background on AVNRT and focus on Emergency Department management. https://media.blubrry.com/coreem/content.blubrry.com/coreem/Episode_20_0_Final.m4a Download 2 Comments Tags: AVNRT, PSVT, REVERT Trial, Tachydysrhythmias Show Notes AVNRT with Aberrancy vs. VT REBEL EM: SVT with Aberrancy Versus VT Amal Mattu's ECG Case of the Week: August 26th, 2013 Valsalva Maneuver ALiEM: Tricks of the Trade: Valsalva Maneuver By Using a 10cc Syringe St. Emlyn's: JC The REVERT Trial Adenosine in AVNRT Larry Mellick: Treating SVT with Adensoine ALiEM: Trick of the Trade: Combining Adenosine with the Flush Verapamil in AVNRT RAGE Podcast:

Atrial fibrillation, atrial flutter, PSVT, PACs